1. SARS-CoV-2 viral RNA detection using the novel CoVradar device associated with the CoVreader smartphone app.
- Author
-
Martín-Sierra C, Chavez MT, Escobedo P, García-Cabrera V, López-Delgado FJ, Guardia-Monteagudo JJ, Ruiz-García I, Erenas MM, Sanchez-Martin RM, Capitán-Vallvey LF, Palma AJ, Pernagallo S, and Diaz-Mochon JJ
- Subjects
- Humans, SARS-CoV-2 genetics, RNA, Viral genetics, RNA, Viral analysis, Pandemics, Smartphone, Nucleic Acid Amplification Techniques methods, COVID-19 diagnosis, Mobile Applications, Biosensing Techniques methods
- Abstract
The COVID-19 pandemic has highlighted the need for innovative approaches to its diagnosis. Here we present CoVradar, a novel and simple colorimetric method that combines nucleic acid analysis with dynamic chemical labeling (DCL) technology and the Spin-Tube device to detect SARS-CoV-2 RNA in saliva samples. The assay includes a fragmentation step to increase the number of RNA templates for analysis, using abasic peptide nucleic acid probes (DGL probes) immobilized to nylon membranes in a specific dot pattern to capture RNA fragments. Duplexes are formed by labeling complementary RNA fragments with biotinylated SMART bases, which act as templates for DCL. Signals are generated by recognizing biotin with streptavidin alkaline phosphatase and incubating with a chromogenic substrate to produce a blue precipitate. CoVradar results are analysed by CoVreader, a smartphone-based image processing system that can display and interpret the blotch pattern. CoVradar and CoVreader provide a unique molecular assay capable of detecting SARS-CoV-2 viral RNA without the need for extraction, preamplification, or pre-labeling steps, offering advantages in terms of time (∼3 h/test), cost (∼€1/test manufacturing cost) and simplicity (does not require large equipment). This solution is also promising for developing assays for other infectious diseases., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JJDM is a founder, shareholder and Director of DESTINA Genomics Ltd. SP is a shareholder of DESTINA Genomics Ltd. DESTINA Genomica SL is a wholly owned subsidiary of DESTINA Genomics Ltd. DESTINA is interested in the exploitation of the technology developed here., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF